REIMIBURSEMENT UNRAVELLED: Will new French medtech innovation plans hit the spot?
This article was originally published in Clinica
Securing reimbursement for innovative medical devices in France calls for high levels of human and financial input. Yet the often cumbersome and misfiring adoption procedures deter manufacturers from approaching this ostensibly attractive medical device market – Europe’s second largest. But Corinne Lebourgeois* explains that a revamped “forfait innovation” might provide the much-needed change
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.